501 related articles for article (PubMed ID: 22991293)
1. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage.
Addison WN; Masica DL; Gray JJ; McKee MD
J Bone Miner Res; 2010 Apr; 25(4):695-705. PubMed ID: 19775205
[TBL] [Abstract][Full Text] [Related]
3. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.
Addison WN; Nakano Y; Loisel T; Crine P; McKee MD
J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632
[TBL] [Abstract][Full Text] [Related]
4. Expression and distribution of SIBLING proteins in the predentin/dentin and mandible of hyp mice.
Zhang B; Sun Y; Chen L; Guan C; Guo L; Qin C
Oral Dis; 2010 Jul; 16(5):453-64. PubMed ID: 20233318
[TBL] [Abstract][Full Text] [Related]
5. A novel Phex mutation in a new mouse model of hypophosphatemic rickets.
Owen C; Chen F; Flenniken AM; Osborne LR; Ichikawa S; Adamson SL; Rossant J; Aubin JE
J Cell Biochem; 2012 Jul; 113(7):2432-41. PubMed ID: 22573557
[TBL] [Abstract][Full Text] [Related]
6. Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice.
Mohamed FF; Hoac B; Phanrungsuwan A; Tan MH; Giovani PA; Ghiba S; Murshed M; Foster BL; McKee MD
Bone; 2023 Nov; 176():116886. PubMed ID: 37634682
[TBL] [Abstract][Full Text] [Related]
7. Genetic Ablation of Osteopontin in Osteomalacic Hyp Mice Partially Rescues the Deficient Mineralization Without Correcting Hypophosphatemia.
Hoac B; Østergaard M; Wittig NK; Boukpessi T; Buss DJ; Chaussain C; Birkedal H; Murshed M; McKee MD
J Bone Miner Res; 2020 Oct; 35(10):2032-2048. PubMed ID: 32501585
[TBL] [Abstract][Full Text] [Related]
8. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
9. Expression and inactivation of osteopontin-degrading PHEX enzyme in squamous cell carcinoma.
Neves RL; Chiarantin GMD; Nascimento FD; Pesquero JB; Nader HB; Tersariol ILS; McKee MD; Carmona AK; Barros NMT
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):155-164. PubMed ID: 27270332
[TBL] [Abstract][Full Text] [Related]
10. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
11. Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures.
Coyac BR; Hoac B; Chafey P; Falgayrac G; Slimani L; Rowe PS; Penel G; Linglart A; McKee MD; Chaussain C; Bardet C
J Dent Res; 2018 Feb; 97(2):184-191. PubMed ID: 28880715
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
13. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate.
David V; Martin A; Hedge AM; Drezner MK; Rowe PS
Am J Physiol Renal Physiol; 2011 Mar; 300(3):F783-91. PubMed ID: 21177780
[TBL] [Abstract][Full Text] [Related]
14. Abnormal osteopontin and matrix extracellular phosphoglycoprotein localization, and odontoblast differentiation, in X-linked hypophosphatemic teeth.
Salmon B; Bardet C; Coyac BR; Baroukh B; Naji J; Rowe PS; Opsahl Vital S; Linglart A; Mckee MD; Chaussain C
Connect Tissue Res; 2014 Aug; 55 Suppl 1():79-82. PubMed ID: 25158186
[TBL] [Abstract][Full Text] [Related]
15. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia.
Coyac BR; Falgayrac G; Baroukh B; Slimani L; Sadoine J; Penel G; Biosse-Duplan M; Schinke T; Linglart A; McKee MD; Chaussain C; Bardet C
Bone; 2017 Oct; 103():334-346. PubMed ID: 28764922
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
17. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
18. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
19. Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers.
Ruchon AF; Tenenhouse HS; Marcinkiewicz M; Siegfried G; Aubin JE; DesGroseillers L; Crine P; Boileau G
J Bone Miner Res; 2000 Aug; 15(8):1440-50. PubMed ID: 10934642
[TBL] [Abstract][Full Text] [Related]
20. Increased Col10a1 expression is not causative for the phenotype of Phex-deficient Hyp mice.
Yorgan T; Rendenbach C; Jeschke A; Amling M; Cheah KS; Schinke T
Biochem Biophys Res Commun; 2013 Dec; 442(3-4):209-13. PubMed ID: 24269824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
